Cancer biology and translational oncology
3 European H2020 organizations list this as part of their work — 2 as their primary capability.
Most active in this area
- MEDIZINISCHE UNIVERSITAET WIEN
Austria's leading medical research university specializing in biomedical imaging (OCT), translational oncology, metabolic disease, and personalised medicine across 120 H2020 projects.
“Projects spanning leukemia (ALKATRAS), breast cancer (HYPMED), colorectal cancer (GlyCoCan), bladder cancer (MIB), and drug discovery through high-throughput screening”
PrimaryAT120 projects - ISTITUTO EUROPEO DI ONCOLOGIA SRL
Milan-based private oncology research hospital specializing in chromatin biology, cancer genomics, and translational epigenetics across 25 EU projects.
“Spans clinical and preclinical work including iManageCancer, FORECEE (cervical cancer prediction), BOUNCE (breast cancer adaptation), CARDIOCARE (cancer cardiotoxicity), OPTIMA (AI-guided treatment), EDIReX (xenograft infrastructure), and oncNGS (NGS diagnostics).”
PrimaryIT25 projects - BIOLUTION GMBH
Vienna biotech SME specializing in thyroid disease and cancer research as an industrial partner in EU consortia.
“Contributed as a third-party partner in ALKATRAS (2015–2019), an MSCA-ITN training network investigating ALK kinase activation as a therapeutic target in cancer.”
SMEAT2 projects